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Abstract: This review focuses on recent advances in the effect of anti-TNFα therapy on bone 
metabolism and bone mineral density (BMD) in rheumatoid arthritis (RA). RA is a chronic 
disease characterized by inﬂ  ammation of the synovial joint, cartilage degradation, and subsequent 
bone destruction. Bone damage is often manifested as erosions, localized juxta-articular bone 
loss, or generalized bone loss. Thus, blockade of TNFa not only serves to block inﬂ  ammation, 
but also halts the erosive nature of RA and generalized/localized juxta-articular bone loss. Here, 
we review recent ﬁ  ndings showing that anti-TNFa therapy is also effective on halting systemic 
bone loss. In vitro, TNFa reduces osteoblast activity and increases osteoclast activity through 
RANKL-RANK pathway. In arthritis animal models, an imbalance between bone formation 
and resorption is observed. In humans, this coupling of destruction is restored by anti-TNFα 
therapy early on, but only for a few months. Thus, anti-TNFα prevents the BMD loss in RA 
patients. In summary, TNFa blockade is not only able to prevent joint destruction, but it is also 
able to prevent bone loss in RA patients. Future studies are needed to address if TNFa blockers 
have an effect on bone fractures.
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Introduction
Rheumatoid arthritis (RA) is a chronic disease characterized by inﬂ  ammation of the 
synovial joint, cartilage degradation, and subsequent bone destruction. Bone damage 
often is manifested as erosions, localized juxta-articular bone loss, or generalized bone 
loss (Kroot et al 2001; Gough et al 1994). The later is likely attributed to a number 
of factors including disease itself, reduced exercise activity, steroids therapy (Laan 
et al 1993; Hall et al 1993; Cortet et al 1997; Haugeberg et al 2002; Mikuls 2003), 
or common postmenopausal osteoporosis. Accelerated generalized bone loss is often 
considered as one of the major complications of RA (Westhovens and Dequeker 2000; 
Green and Deodhar 2001; Sambrook et al 1987; Goldring and Gravallese 2000), as 
patients often have an increased risk of hip (Cooper et al 1995; Huusko et al 2001; 
van Staa et al 2006) or vertebral fractures (Spector et al 1993; Peel et al 1995; van 
Staa et al 2006). Blockade of mediators of joint inﬂ  ammation is a promising strategy 
to halt or perhaps improve the severity of these bone related manifestations.
TNFα a key cytokine target
For almost a decade, anti-TNFα therapy has established a new standard in RA therapy, 
creating new objectives for disease remission on both the clinical and radiological 
level. Currently, three anti-TNFα drugs are commercially available and have been 
successfully used in halting both joint inﬂ  ammation and destruction in RA patients 
(Charles et al 1999; Maini et al 1999; Weinblatt et al 1999; Genovese et al 2002; Biologics: Targets & Therapy 2008:2(4) 664
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Lipsky et al 2000; Keystone et al 2004; Smolen et al 2005). 
Furthermore TNFα plays a central role not only in RA, but 
also in common osteoporosis. In fact, TNFα has been shown 
to increase bone resorption in systemic osteoporosis related 
to oestrogen deﬁ  ciency (Paciﬁ  ci and Avioli 1993). In addi-
tion, transgenic mice expressing soluble TNFα receptor to 
neutralize TNFα, were protected from oestrogen deﬁ  ciency-
related bone loss (Ammann et al 1997). Thus, blockade 
of  TNFα not only serves to block inﬂ  ammation, but also 
halts the erosive nature of RA and generalized/localized 
juxta-articular bone loss. Here, we review recent ﬁ  ndings 
showing that anti-TNFα therapy is also effective on halting 
systemic bone loss.
In vitro effects of  TNFα 
on osteoblasts and osteoclasts 
(Figure 1)
Over the last two decades, there have been a number of ﬁ  nd-
ings on the effects of TNFα on osteoblast activity. These 
include the different down regulatory effects of TNFα on 
osteoblasts: differentiation, mineralization, and expression 
of the skeletal bone matrix (Bertolini et al 1986; Nguyen 
et al 1991; Taichman and Hauschka 1992; Kuroki et al 1994; 
Nakase et al 1997; Gilbert et al 2000, 2002). Furthermore, 
TNFα stimulation also induces apoptosis in osteoblasts (Hill 
et al 1997; Jilka et al 1998).
Research on the development of bone erosions has rap-
idly increased over recent years. First was the detection of 
osteoclasts at sites of arthritic bone erosion (Ishikawa et al 
1984). Second was the discovery of the balance between 
TNF superfamily molecules: osteoprotegerin (OPG), recep-
tor activator of nuclear factor κB ligand (RANKL), receptor 
activator of nuclear factor κB (RANK), and TNF-related 
apoptosis inducing ligand (Gravallese et al 2000; Kong 
et al 1999, 2000; Hofbauer and Heufelder 2001). RANKL 
is a transmembrane receptor protein and its inhibition by 
osteoprotogerin (OPG), a decoy receptor, has important 
implications for inﬂ  ammation research as well as for bone 
physiology (Kong et al 1999; Emery et al 1998).
Osteoblasts express RANKL constitutively on their 
cell surface. RANKL interacts with its cognate receptor 
RANK, which is expressed on osteoclast precursors and 
promotes osteoclast differentiation. Interaction of RANKL 
with RANK on mature osteoclasts results in their activation 
and prolonged survival. Importantly, osteoclasts are clearly 
the principal instruments of this destruction. As shown by 
studies using osteoclast deﬁ  cient animal models of disease, 
treatment with antiresorptive agents such as OPG, delays 
bone damage in vivo (Joosten et al 1999; Kong et al 1999; 
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Figure 1 Increasing the balance of receptor activator of nuclear factor κB ligand (RANKL)-receptor activator of nuclear factor κB (RANK) induced by tumor necrosis factor 
alpha (TNFα).
Abbreviations: OPG, osteoprotegerin; +, stimulation; –, inhibition.Biologics: Targets & Therapy 2008:2(4) 665
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Pettit et al 2001; Gravallese 2002; Redlich et al 2002b; 
Saidenberg-Kermanac’h et al 2004).
RANKL also plays a key role in the regulation of osteo-
clastogenesis, osteoclast activation, dendritic cell survival, 
lymphocyte development, and lymph node organogenesis 
(Kong et al 1999). Studies showing that the RANKL/RANK 
ratio regulates osteoclastogenesis have profoundly inﬂ  u-
enced our current understanding of inﬂ  ammation mediated 
bone loss (Kong et al 1999; Gravallese et al 1998, 2000; 
Shigeyama et al 2000; Takayanagi et al 2000; Redlich et al 
2002a; Romas et al 2002; Pettit et al 2001). OPG deﬁ  cient 
mice exhibit massive osteoporosis and also develop calci-
ﬁ  ed lesions in the aorta and renal arteries (Bucay et al 1998; 
Min et al 2000). In contrast, the overexpression of OPG in 
transgenic mice results in severe osteopetrosis and spleno-
megaly (Min et al 2000). The inhibition of  bone resorption 
by the administration of OPG has been demonstrated in 
postmenopausal women (Bekker et al 2001) and in mice 
challenged with interleukin-1β (IL-1β) or TNFα (Morony 
et al 1999). Treatment with anti-RANKL antibody has also 
resulted in an increased amount of bone mineral density 
(BMD) (McClung et al 2006).
TNFα elevates RANKL expression in numerous cell 
types: stroma cells, synoviocytes, osteoblasts, endothelial 
cells, human microvascular endothelial cells, T cells, and 
B cells (Hofbauer et al 1998; Cenci et al 2000; Kanematsu 
et al 2000 Nakashima et al 2000; Page and Miossec 2005; 
Collin-Osdoby et al 2001). TNFα also has differential effects 
on OPG expression depending on cell type: a decrease is 
observed in osteoblasts/stromal cells (Nakashima et al 2000), 
while an increase is observed in endothelial cells (Collin-
Osdoby et al 2001), osteoblast cells (Hof bauer et al 1998), 
and in RA synoviocytes (Marotte et al 2005). In this later, 
an inhibition of this stimulation is observed when inﬂ  iximab 
is added (Marotte et al 2005).
RA and psoriatic arthritis have a marked increase in the 
number of pre-osteoclasts in their peripheral blood mononu-
clear cell populations compared to normal and osteoarthritis 
controls (Ritchlin et al 2003). Importantly, this increase also 
appears to be reversible with anti-TNFα therapy, and may be 
a predominant mechanism by which this treatment inhibits 
erosions in these patients.
Unbalance between bone formation 
and resorption in arthritis model
Much less is known about bone formation in animal models 
of immune-mediated arthritis. Given the insidious erosive 
course of these conditions, it is obvious that bone resorption 
outweighs bone formation. However, bone formation is 
strongly down-regulated during chronic arthritis. For exam-
ple, studies in animal models, which addressed systemic bone 
changes, showed reduction in bone formation in femurs by 
histomorphometry as well as low serum levels of the bone 
formation marker, osteocalcin (OC) (Bonnet et al 1993; 
Hoshino et al 2001). Furthermore, blocking TNFα prevents 
bone loss in animal models and increases trabecular thickness 
(Joosten et al 1999; Saidenberg-Kermanac’h et al 2004).
Effect of anti-TNFα on bone 
markers
As shown above, bone remodeling is the result of two 
opposing activities, the production of new bone matrix by 
osteoblasts and the destruction of old bone by osteoclasts. 
Biochemical markers of bone turnover are substances in the 
blood or urine that are produced or released during bone 
remodeling. They provide semi-quantitative information 
on bone remodeling. At present, the most speciﬁ  c markers 
for bone formation are serum OC, bone-speciﬁ  c alkaline 
phosphate (BAP), and procollagen type I N-terminal pro-
peptide (PINP). OC is down regulated by steroid therapy 
(Vergely et al 2002), whereas BAP and PINP changes are 
not linked to this therapy (Cortet et al 2001). For the evalu-
ation of bone resorption, numerous serum markers of type 
I collagen telopeptide epitopes (CTX-I, NTX-I, and ICTP) 
and deoxypyridinoline are currently used. Among them, 
C-telopeptides (CTX-I and ICTP) are the most sensitive 
markers of bone resorption (Garnero and Delmas 2004). 
By two different enzymatic pathways, two C-telopeptide 
fragments are released from bone type I collagen (Sassi 
et al 2000; Garnero et al 2003). ICTP is generated by matrix 
metalloproteases whose activity plays an important role in 
collagen degradation associated with RA (Brennan et al 
1997). In contrast, CTX-I is generated by cathepsin K, which 
is the key osteoclastic enzyme for systemic bone resorption 
(Inui et al 1997).
Several cross-sectional studies in human RA support 
these experimental ﬁ  ndings. RA patients have signiﬁ  cantly 
lower osteocalcin levels than healthy controls (Al-Awadhi 
et al 1999; Garnero et al 1999; Seriolo et al 2002). Indeed, in 
one of our previous studies (Garnero et al 1999), uncoupling 
between bone destruction and formation was observed in 
destructive RA, whereas such uncoupling was not observed in 
benign non-destructive RA. It now appears that TNFα inhibi-
tion may restore this coupling of destruction with formation. 
Initial clinical studies on the effect of TNFα blockers on bone 
focused primarily on bone markers. Bone formation markers Biologics: Targets & Therapy 2008:2(4) 666
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(OC and PINP) showed an early increase at 2 and 6 weeks 
after initiation of inﬂ  iximab treatment in a study conducted 
in 68 RA patients (Vis et al 2003), whereas only ICTP was 
down regulated at 6 weeks despite having negligible effects 
on CTX-I. The long-term effect of inﬂ  iximab at 1 year was 
described in a small population of 26 patients with RA 
(Lange et al 2005), with a persistent increase in OC and a 
persistent decrease in CTX-I. However, in another study of 
70 patients with RA treated with inﬂ  iximab plus methotrex-
ate, a decrease was observed only in bone resorption markers 
(urinary excretion of NTX-I and deoxypyridinoline), whereas 
BAP did not increase (Torikai et al 2006). The same pattern 
with a rapid decrease of CTX-I levels followed by a return 
to baseline levels at 1 year was observed in several studies 
in RA (Lange et al 2005; Vis et al 2005, 2006; Chopin et al 
2007), and also in spondylarthropathy (Briot et al 2005). 
Only one study explored the changes of CTX-I and ICTP 
under inﬂ  iximab over one year (Chopin et al 2007). ICTP 
level showed a later decrease compared to CTX-I, suggest-
ing different speciﬁ  c resorption processes. In another study, 
inﬂ  iximab therapy had a less signiﬁ  cant effect on serum 
OPG and sRANKL levels in RA patients (Ziolkowska et al 
2002). Recently, decreases in CTX-I and sRANKL on serum 
were observed over 1 year of inﬂ  iximab treatment (Vis et al 
2006). In summary, early changes in bone remodeling under 
inﬂ  iximab was characterized by an uncoupled response with 
TNFα inhibition inducing a decrease in bone resorption. 
This was followed by a secondary steady-state with higher 
resorption level to match bone formation. Finally, the ratio 
between markers of bone formation and bone resorption 
appeared to be increased.
Effect of anti-TNFα on BMD
Bone mineral density (BMD) can be assessed by numerous 
methods, but dual x ray absorptiometry (DXA) is consid-
ered the “gold standard” (Genant et al 1996). In practice, 
lumbar spine (L1-4) and total hip are measured after a daily 
calibration using an external phantom to detect a machine 
drift. For longitudinal studies, several assessments need to 
be performed in the same bone densitometer.
High BMD loss in RA patients was associated with joint 
damage progression, disease activity, functional disability 
Table 1 Effect of   TNFα and anti-TNFα on bone cells, bone biomarkers, X-rays, and bone mineral density
TNFα Anti-TNFα
In vitro Osteoblasts Inhibition of differentiation (Gilbert et al 2000; Gilbert et al 
2002)
Inhibition of mineralization (Taichman and Hauschka; 1992; 
Kuroki et al 1994; Nakase et al 1997)
Skeletal bone matrix synthesis:inhibition (Taichman and 
Hauschka 1992; Kuroki et al 1994; Nakase et al 1997;   Yudoh et al 
2000)
Induction of apoptosis (Hill et al 1997;
Jilka et al 1998)
Stimulation of RANKL expression (Nakashima et al 2000; 
Hofbauer et al 1998)
?
Osteoclasts Activation via RANK/RANKL ?
Increasing of OPG production (Collin-Osdoby et al 2001; 
Hofbauer et al 1998; Marotte et al 2005)
Decreasing of OPG production (Nakashima et al 2000)
Decrease of OPG production
(Marotte et al 2005)
In vivo Biomarkers 
of bone 
remodeling
Decreasing of biomarkers of bone formation (Bonnet et al 1993)
Increasing of biomarkers of bone resorption (Saidenberg-
Kermanac’H et al 2004;  Joosten et al 1999)
Early restoration of the balance between 
biomarkers of bone formation and resorp-
tion (Lange et al 2005;   Vis et al 2005;   Vis et al 
2006; Chopin et al 2007)
X-rays Erosion progression No erosion progression (Smolen et al 2005; 
Genovese et al 2002; Keystone et al 2004; 
Lipsky et al 2000)
Bone 
mineral 
density
Bone loss Prevention of bone loss (Marotte et al 2007)
Abbreviations: TNFα, tumor necrosis factor alpha; RANKL, receptor activator of nuclear factor κB ligand; RANK, receptor activator of nuclear factor κB; OPG, 
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and immobility in previous longitudinal studies, even in early 
RA (Gough et al 1994; Shenstone et al 1994; Cortet et al 
2000; Forslind et al 2003; Jensen et al 2004). However, sev-
eral observational studies were performed without enrolled 
control groups. The ﬁ  rst studies enrolled a small number 
of patients, and showed an increase of BMD in numerous 
inﬂ  ammatory disorders. In patients with RA (n = 26) (Lange 
et al 2005), with spondylarthropathy (n = 29) (Allali et al 
2003) and with Crohn’s disease (n = 46) (Bernstein et al 
2005), a signiﬁ  cant increase of BMD values was observed. 
Another study enrolled 102 RA patients in an open prospec-
tive cohort. After 1 year of inﬂ  iximab therapy, no bone loss 
was observed in the spine and hip, while a decrease of  BMD 
was observed at the hands (Vis et al 2006). Unfortunately, 
no control group was used in the study.
The lack of a control group is a major limitation for pre-
dicting a true estimation of the effect of anti-TNFα treatment 
on bone. The gold standard for this type of study would be 
a double blind randomized vs placebo trial. However, since 
TNFα blockers are now on the market, ethical issues would 
prevent such a randomized vs placebo trial. In order to have a 
control population for such a study, we used another option. 
We performed a historical control study, composed of active 
RA patients followed before the time of TNFα blockers 
and treated with methotrexate alone (Marotte et al 2007). 
This historical control group is of critical interest because 
it was not inﬂ  uenced by the use of TNFα inhibitors. In the 
control group (n = 99), we found a signiﬁ  cant decrease of 
BMD (-3.4% at the femoral neck and -3.9% at lumbar spine, 
p  0.001), while no decrease was observed in the group 
treated by methotrexate and inﬂ  iximab. Similar results were 
observed when putative cofactors are considered (sex status, 
age, menopause status, steroids or biphosphonate therapy, 
and RA activity). Furthermore, there was no signiﬁ  cant 
difference in BMD changes between responders and non 
responders. For the non responders, the change in lumbar 
spine BMD was +0.4% vs –0.8% for the responders. Same 
trend was observed in femoral neck with BMD change at 
+2.0% in the non-responders vs –0.4% in the responders. 
This protective effect observed in clinical non responders to 
inﬂ  iximab is in accordance with the ﬁ  ndings of a recent study 
(Lipsky et al 2000; Genovese et al 2002; Keystone et al 2004; 
Smolen et al 2005) that demonstrated protective effects on 
joint destruction in the absence of clinical response.
Since our study, new data is available coming from the 
BeSt study, which is a multicenter, randomized clinical trial 
designed to compare the effectiveness of four different treat-
ment strategies in patients with recently diagnosed, active 
RA (Guler-Yuksel et al 2008). The main ﬁ  nding of this study 
was that there were no differences between the treatment 
groups. Again in this study, no appropriate control group 
was used according to ethical issues. Furthermore, the lack 
of bone loss in the group with steroids can be explained in 
part by the large prescription of biphosphonate therapy in 
this subgroup.
Conclusion
In summary, TNFα blockade is not only able to prevent 
joint destruction, but it is also able to prevent bone loss in 
RA patients. Future studies are needed to address if  TNFα 
blockers have an effect on bone fractures.
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